About Inflammatory Bowel Disease
Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn's disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss. Inflammatory bowel disease can also prove to be life-threatening for the patients. Ulcerative colitis generally affects the colon, where inflammation and ulcers develop in the innermost lining of the colon and the rectum of a patient. Crohn's disease causes inflammation of the lining of the GI tract. The inflammation in Crohn's disease affects various areas of the GI tract such as the large intestine and small intestine, or both. Inflammatory bowel disease is a chronic medical condition, which has no permanent cure and demands a lifetime of treatment and management. The preferred treatment options include anti-inflammatory steroidal products and immuno-suppressive agents such as the TNF-α inhibitors.
TechNavio's analysts forecast the Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis.
On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments.
• 5-ASA
• Antibiotics
• Immunomodulators
On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.
• Biologics
• Small Molecules
On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.
• Oral
• Parenteral
On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments.
• Solid
• Liquid
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Inflammatory Bowel Disease market. The vendor landscape includes an analysis of the major vendors, along with the competitive performances of their portfolios. In addition, the report discusses the major drivers, challenges and trends influencing the market. In addition, late-stage pipeline molecules developed for the treatment of inflammatory bowel disease are discussed.
TechNavio's report, Global Inflammatory Bowel Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the landscape of the Global Inflammatory Bowel Disease market and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Abbvie
• Biogen Idec
• Janssen Pharmaceuticals
• Merck & Company
• Shire
• UCB
Other Prominent Vendors
• Amgen
• Akebia Therapeutics
• Boehringer Ingelheim
• Celltrion
• ChemoCentryx
• Ferring Pharmaceuticals
• Galapagos
• Genentech
• Merck
• Mitsubishi Tanabe
• Novartis
• Novo Nordisk
• Pfizer
• Salix Pharmaceuticals
Market Driver
• Increase in Instances of Inflammatory Bowel Disease
• For a full, detailed list, view our report
Market Challenge
• High Cost of Drugs
• For a full, detailed list, view our report
Market Trend
• Dominance of Market by Biologics
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview: Crohn's Disease
06.1 Understanding the Disease
06.2 Etiology
06.2.1 Autoimmune Reaction
06.2.2 Genes
06.2.3 Environment
06.3 Stages of Crohn's disease
06.4 Epidemiology
06.4.1 Worldwide Prevalence of Crohn's Disease
06.4.2 US
06.4.3 UK
06.5 Symptoms
06.5.1 Diarrhea
06.5.2 Fever and Fatigue
06.5.3 Abdominal Pain and Cramping
06.5.4 Perianal Disease and Blood in Stool
06.5.5 Reduced Appetite and Weight Loss
06.6 Diagnosis and Testing
06.6.1 Early Tests and Exams
06.6.2 Endoscopy and Biopsy
06.6.3 Chromoendoscopy
06.6.4 Small Intestinal Imaging
06.7 Treatment
06.7.1 Medication
06.7.2 Diet and Nutrition
06.7.3 Surgery
07. Disease Overview: Ulcerative Colitis
07.1 Understanding the Disease
07.2 Etiology
07.2.1 Autoimmune Reaction
07.2.2 Genetics
07.2.3 Environmental Factors
07.3 Prognosis
07.4 Epidemiology
07.4.1 Global
07.4.2 UK
07.4.3 US
07.5 Symptoms
07.6 Diagnosis and Testing
07.7 Treatment
07.7.1 Medical Treatment Options
07.7.2 Surgical Procedures
08. Pipeline Portfolio
08.1 Crohn's Disease Pipeline Landscape
08.1.1 Some Emerging Therapeutic Options
08.2 Ulcerative Colitis Pipeline Landscape
09. Market Landscape
09.1 Global Inflammatory Bowel Disease Market
09.2 Market Size and Forecast
09.3 Inflammatory Bowel Disease Market in US
09.3.1 Market Size and Forecast
09.4 Inflammatory Bowel Disease Market in 5EU
09.4.1 Market Size and Forecast
09.5 Inflammatory Bowel Disease Market in Japan
09.5.1 Market Size and Forecast
10. Market Segmentation by Type of Disease
10.1 Crohn's Disease
10.2 Ulcerative Colitis
11. Global Crohn's Disease Market
11.1 Market Size and Forecast
11.2 Crohn's Disease Market in US
11.2.1 Market Size and Forecast
11.3 Crohn's Disease Market in Japan
11.3.1 Market Size and Forecast
12. Global Ulcerative Colitis Market
12.1 Market Size and Forecast
12.2 Five Forces Analysis
13. Market Segmentation by Drug Class
14. Market Segmentation by Type of Molecules
14.1 Biologics
14.2 Small Molecules
15. Market Segmentation by Dosage Form
15.1 Solid
15.2 Liquid
16. Market Segmentation by Route of Administration
16.1 Oral
16.2 Parenteral
17. Geographical Segmentation
17.1 Geographic Segmentation of Global Crohn's Disease Market
17.2 Geographic Segmentation of Global Ulcerative Colitis Market
18. Key Leading Countries
18.1 Key Leading Countries 2014
18.2 Key Leading Countries 2019
18.3 US
18.4 Japan
19. Buying Criteria
20. Market Growth Drivers
21. Drivers and their Impact
22. Market Challenges
23. Impact of Drivers and Challenges
24. Market Trends
25. Trends and their Impact
26. Vendor Landscape
26.1 Competitive Scenario
26.1.1 Key News
26.1.2 Mergers and Acquisitions
26.2 Market Share Analysis 2014
26.2.1 Competitive Assessment of Top Drugs for Inflammatory Bowel Disease
26.2.2 Abbvie
26.2.3 Janssen Pharmaceuticals
26.2.4 Merck
26.2.5 Biogen Idec
26.2.6 UCB
26.2.7 Shire
26.3 Other and Future Prominent Vendors
27. Key Vendor Analysis
27.1 AbbVie Inc.
27.1.1 Key Facts
27.1.2 Business Overview
27.1.3 Product Segmentation by Revenue 2013
27.1.4 Product Segmentation by Revenue 2012 and 2013
27.1.5 Sales by Geography
27.1.6 Business Strategy
27.1.7 Key Developments
27.1.8 SWOT Analysis
27.2 Biogen Idec
27.2.1 Key Facts
27.2.2 Business Overview
27.2.3 Business Segmentation by Revenue 2013
27.2.4 Geographical Segmentation by Revenue 2013
27.2.5 Business Strategy
27.2.6 Key Developments
27.2.7 SWOT Analysis
27.3 Janssen Pharmaceuticals
27.3.1 Key Facts
27.3.2 Business Overview
27.3.3 Recent Developments
27.3.4 SWOT Analysis
27.4 Merck
27.4.1 Key Facts
27.4.2 Business Overview
27.4.3 Business Segmentation by Revenue 2013
27.4.4 Business Segmentation by Revenue 2012 and 2013
27.4.5 Sales by Geography
27.4.6 Business Strategy
27.4.7 Key Developments
27.4.8 SWOT Analysis
27.5 Shire
27.5.1 Key Facts
27.5.2 Business Overview
27.5.3 Geographical Segmentation by Revenue 2013
27.5.4 Business Strategy
27.5.5 Recent Developments
27.5.6 SWOT Analysis
27.6 UCB
27.6.1 Key Facts
27.6.2 Business Overview
27.6.3 Product Segmentation by Revenue 2013
27.6.4 Product Segmentation by Revenue 2012 and 2013
27.6.5 Geographical Segmentation by Revenue 2013
27.6.6 Business Strategy
27.6.7 Recent Developments
27.6.8 SWOT Analysis
28. Other Reports in this Series
Exhibit 1: Market Research Methodology
Exhibit 2: Drivers and Challenges of the Global Inflammatory Bowel Disease Market
Exhibit 3: Overview of Crohn's disease
Exhibit 4: Classification of Crohn's disease
Exhibit 5: Expected Number of Global Crohn's Disease Cases 2015-2022
Exhibit 6: Global Variation in Incidence Rates for Crohn's Disease in 2012 (percent)
Exhibit 7: Prevalence of Crohn's Disease in US
Exhibit 8: Incidence of Crohn's Disease in US
Exhibit 9: Symptoms of Crohn's Disease
Exhibit 10: Crohn's Disease: Diagnosis and Testing
Exhibit 11: Crohn's Disease: Treatment
Exhibit 12: Treatment Landscape for Crohn's Disease
Exhibit 13: Crohn's Disease: Treatment Pathway
Exhibit 14: Ulcerative Colitis: Symptoms
Exhibit 15: Diagnostic Approach for Ulcerative Colitis
Exhibit 16: Treatment Options for Inflammatory Bowel Disease
Exhibit 17: Surgical procedure to treat Ulcerative Colitis
Exhibit 18: Crohn's Disease: Pipeline Portfolio
Exhibit 19: Crohn's Disease Clinical Trial by Phase
Exhibit 20: Crohn's Disease Clinical Trial by Status
Exhibit 21: Crohn's Disease: Pipeline Portfolio
Exhibit 22: Snapshot of Global Inflammatory Bowel Disease Market 2014
Exhibit 23: Global Inflammatory Bowel Disease Market 2014-2019 (US$ million)
Exhibit 24: Inflammatory Bowel Disease Market in US 2014-2019 (US$ million)
Exhibit 25: Inflammatory Bowel Disease Market in 5EU 2014-2019 (US$ million)
Exhibit 26: Inflammatory Bowel Disease Market in Japan 2014-2019 (US$ million)
Exhibit 27: Segmentation of Global Inflammatory Bowel Disease Market by Type of Disease
Exhibit 28: Segmentation of Global Inflammatory Bowel Disease Market by Type of Disease 2014
Exhibit 29: Segmentation of Global Inflammatory Bowel Disease Market by Type of Disease 2019
Exhibit 30: Revenue Comparison of Global Inflammatory Bowel Disease Market (Crohn's Disease and Ulcerative Colitis) 2014-2019 (US$ million)
Exhibit 31: Snapshot of Global Crohn's Disease Market 2014
Exhibit 32: Global Crohn's Disease Market 2014-2019 (US$ million)
Exhibit 33: Crohn's Disease Market in US 2014-2019 (US$ million)
Exhibit 34: Crohn's Disease Market in Japan 2014-2019 (US$ million)
Exhibit 35: Snapshot of the Global Ulcerative Colitis Market
Exhibit 36: Global Ulcerative Colitis Market 2014-2019 (US$ million)
Exhibit 37: Segmentation of Global Inflammatory Bowel Disease Market by Drug Class
Exhibit 38: Benefits and Risks of 5-ASA
Exhibit 39: Segmentation of Global Inflammatory Bowel Disease Market by Drug Class 2014
Exhibit 40: Segmentation of Global Inflammatory Bowel Disease Market by Type of Molecules
Exhibit 41: Segmentation of Global Inflammatory Bowel Disease Market by Type of Molecules 2014
Exhibit 42: Segmentation of Global Inflammatory Bowel Disease Market by Dosage Form
Exhibit 43: Segmentation of Global Inflammatory Bowel Disease Market by Dosage Form 2014
Exhibit 44: Segmentation of Global Inflammatory Bowel Disease Market by Route of Administration
Exhibit 45: Segmentation of Global Inflammatory Bowel Disease Market by Route of Administration 2014
Exhibit 46: Segmentation of Global Inflammatory Bowel Disease Market by Geography 2014
Exhibit 47: Segmentation of Global Inflammatory Bowel Disease Market by Geography 2019
Exhibit 48: Segmentation of Global Crohn's Disease Market by Geography 2014
Exhibit 49: Segmentation of Global Ulcerative Colitis Market by Geography 2014
Exhibit 50: Global Inflammatory Bowel Disease Market Share Analysis 2014
Exhibit 51: YoY Revenue Comparison of Top Drugs for Inflammatory Bowel Disease 2010-2014 (US$ million)
Exhibit 52: Revenue Share of Top Drugs for Inflammatory Bowel Disease 2010-2014 (in percentage)
Exhibit 53: Abbvie: Product Portfolio for Inflammatory Bowel Disease
Exhibit 54: YoY Global Revenue of Humira 2009-2014 (US$ million)
Exhibit 55: YoY Revenue of Humira in US 2009-2014 (US$ million)
Exhibit 56: YoY International Revenue of Humira (Except US) 2009-2014 (US$ million)
Exhibit 57: Global Revenue Comparison of Humira 2009-2014 (US$ million)
Exhibit 58: Janssen: Product Portfolio for Inflammatory Bowel Disease
Exhibit 59: YoY Global Revenue of Remicade 2009-2014 (US$ million)
Exhibit 60: YoY Global Revenue of Simponi 2010-2014 (US$ million)
Exhibit 61: Merck: Product Portfolio for Inflammatory Bowel Disease
Exhibit 62: YoY Global Revenue of Remicade 2009-2014 (US$ million)
Exhibit 63: YoY Global Revenue of Simponi 2010-20134(US$ million)
Exhibit 64: Biogen Idec: Product Portfolio for Inflammatory Bowel Disease
Exhibit 65: YoY Global Revenue of Tysabri 2009-2014 (US$ million)
Exhibit 66: YoY Revenue of Tysabri in US 2009-2014 (US$ million)
Exhibit 67: YoY Revenue of Tysabri in ROW 2009-2014 (US$ million)
Exhibit 68: Global Revenue Comparison of Tysabri 2009-2014 (US$ million)
Exhibit 69: UCB: Product Portfolio for Inflammatory Bowel Disease
Exhibit 70: YoY Global Revenue of Cimzia 2010-2014 (US$ million)
Exhibit 71: Shire: Product Portfolio for Inflammatory Bowel Disease
Exhibit 72: YoY Global Revenue of Lialda 2010-2014 (US$ million)
Exhibit 73: AbbVie Inc.: Product Segmentation by Revenue 2013
Exhibit 74: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 75: AbbVie Inc.: Sales by Geography 2013
Exhibit 76: Biogen Idec: Business Segmentation by Revenue 2013
Exhibit 77: Biogen Idec: Geographical Segmentation by Revenue 2013
Exhibit 78: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 79: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 80: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 81: Shire: Geographical Segmentation by Revenue 2013
Exhibit 82: UCB: Product Segmentation by Revenue 2013
Exhibit 83: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 84: UCB: Geographical Segmentation by Revenue 2013
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950